Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and in Spain

International Journal of Clinical Practice

Volumn 59, Issue 1, 2005, Pages 62-68

  Lindgren, Björn ^a   Sears, M R ^b   Campbell, M ^c   Villasante, C ^d   Huang, S ^e   Lindh, A ^f   Petermann, W ^f   Svensson, K ^g   Berggren, F ^g   Pauwels, R A ^h  

^a LUND UNIVERSITY   (Sweden)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^f Husläkarna Österåker ^*  (Germany)

^g ASTRAZENECA R AND D   (Sweden)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Asthma; Cost effectiveness; Formoterol; RELIEF; Reliever; Salbutamol; Spain; Sweden

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; FORMOTEROL; INSPIRYL; MONTELUKAST; NEDOCROMIL; SALBUTAMOL; ZAFIRLUKAST;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPAIN; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SWEDEN;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; ETHANOLAMINES; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; SEVERITY OF ILLNESS INDEX; SPAIN; SWEDEN;

EID: 13844321748     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2005.00347.x     Document Type: Article

References (21)

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. National Institutes of Health, National Heart, Lung and Blood Institute 1995: 1-176 (publication no. 95-3659).
2. British Thoracic Society. The British guidelines on asthma management. Thorax 1997; 52 (Suppl. 1): 1-21.
3. Svedmyr N, Löfdahl CG. Physiology and pharmacokinetics of beta-adrenergic agonists. In: Jenne JW, Murphy S, eds. Drug Therapy for Asthma. New York: Dekker, 1987: 177-211.
4. Ringdal N, Derom E, Wåhlin-Boll E, Pauwels R. Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med 1998; 92: 1017-21.
5. Pauwels RA, Campbell M, Villasante C et al. A comparison of salbutamol and formoterol as a reliever medication in asthma: a worldwide, randomised, effectiveness trial. Eur Respir J 2003; 22 (5): 787-94.
6. Banta HD, Luce BR. Health Care Technology and its Assessment. New York: Oxford University Press, 1993.
7. Gerdtham UG, Hertzman P, Jönsson B, Boman G. Impact of inhaled corticosteroids on asthma hospitalisation in Sweden 1978 to 1991. Med Care 1996; 34: 1188-98.
8. Tattersfield AE, Löfdahl CG, Postma DS et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357: 257-61.
9. Berggren F, Ekström T. A cost-effectiveness study comparing the as-needed use of formoterol (Oxis) and terbutaline (Bricanyl) in patients with moderate to severe asthma. Respir Med 2001; 95: 753-8.
10. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines - similarities, differences and some implications. Value Health 2001; 4: 225-50.
11. Sullivan SD, Weiss KB. Health economics of asthma and rhinitis. II. Assessing the value of interventions. J Allergy Clin Immunol 2001; 107: 203-10.
12. O'Byrne PM, Barnes PJ, Rodriguez-Rosisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma. The OPTIMA randomised trial. Am J Respir Crit Care Med 2001; 164: 1392-7.
13. Efron B, Tibshirani RJ. An Introduction to the Bootstrap New York: Chapman & Hall, 1993.
14. Sullivan SD, Liljas B, Buxton M et al. Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial. Controlled Clin Trials 2001; 22: 420-37.
15. Gold RG, Russell LR, Siegel JE et al. Cost-effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
16. Sullivan S, Elixhauser A, Buist S, Luce BR, Eisenberg J, Weiss K. National Asthma Education and Prevention Program, working group report on the cost effectiveness of asthma care. Am J Respir Crit Care Med 1996; 154: S84-S95.
17. Persson U, Ghatnekar O. Cost-effectiveness analysis of inhaled corticosteroids in asthma. A review of the analytical standards. Respir Med 2003; 97: 1-11.
18. Molken MP, van Doorslaer EK, Rutten FF. Economic appraisal of asthma and COPD care: a literature review 1980-1991. Soc Sci Med 1992; 35: 161-75.
19. Bryan S, Buxton MJ. Economic evaluation of treatments for respiratory disease. Pharmacoeconomics 1992; 2: 207-18.
20. The National Institute of Clinical Excellence. Clinical and cost effectiveness of inhaler devices for children with chronic asthma. NHS R&D HTA Programme, 2000 (available at http://www.nice.org.uk).
21. Behandling av asthma och KOL. En systematisk kunskapssammanställning (in Swedish; Treatment of asthma and COPD. A systematic review). Statens beredning för medicinsk utvärdering. Stockholm: The Swedish Council on Technology Assessments in Health Care, Redners, 2000.